| 01.12.22 | J&J inks oral biologics pact with Sanofi ally; 2seventy picks LNP tech for Novo Nordisk project

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

2 jahre vor

Html
Text

Webinar: How to choose the appropriate pre-filled syringe and enhanced delivery system for your product

Wednesday, January 19 | 11 am ET / 8am PT

In an environment that calls for more convenient delivery systems, we will guide you on how to make the right choice for your product. This webinar will cover selection criteria for pre-filled syringes and enhanced delivery systems. Register to learn more.

Today's Rundown

J&J, following in Sanofi's footsteps, tasks i2o with oral delivery of large molecules 2seventy brings in Genevant delivery tech for Novo Nordisk in vivo gene editing project Kyowa sells U.S. rights to cancer drug delivery patch to Cumberland Selecta taps Ginkgo to create better capsids for gene therapy delivery Teva, Sandoz have launched Narcan generics, but Emergent's branded option should still thrive: analysts

Featured Story

J&J, following in Sanofi's footsteps, tasks i2o with oral delivery of large molecules

By Nick Paul Taylor

Big Pharma’s embrace of i2o Therapeutics continues. After signing up Sanofi last year, the spinout from Harvard University has started 2022 by disclosing a deal to work with Johnson & Johnson on oral delivery of macromolecules.

Webinar: The Road to Going Public and Beyond: Preparation starts now

Tuesday, February 8, 2022 | 2pm ET / 11am PT

The path to going public is complex and requires significant time to plan and execute to success. Join us to learn about the latest trends in the public markets, as well as the steps you can take now to prepare your organization for IPO when the market opportunity arises. Register now.

2seventy brings in Genevant delivery tech for Novo Nordisk in vivo gene editing project

By Nick Paul Taylor

Bluebird bio’s oncology spinoff has secured rights to a lipid nanoparticle delivery technology from Genevant Sciences. The spinoff, 2seventy bio, will use the delivery technology in an in vivo gene editing collaboration with Novo Nordisk.

Kyowa sells U.S. rights to cancer drug delivery patch to Cumberland

By Nick Paul Taylor

Kyowa Kirin has sold its FDA-approved oncology patch to Cumberland Pharmaceuticals. The deal will give Cumberland the U.S. rights to Sancuso, a product that delivers a drug through the skin to stop nausea, in return for $13.5 million upfront plus milestones and royalties.

Selecta taps Ginkgo to create better capsids for gene therapy delivery

By Nick Paul Taylor

Selecta Biosciences and Ginkgo Bioworks are extending their alliance to cover gene therapy delivery. Just months after disclosing a rare disease pact, the partners have unwrapped a second deal focused on the development of gene therapy capsids that address the limitations of current delivery vehicles.

Teva, Sandoz have launched Narcan generics, but Emergent's branded option should still thrive: analysts

By Kevin Dunleavy

On the same day in December, Teva and Sandoz launched copycat versions of Emergent's opioid overdose nasal spray Narcan, suggesting its reign of dominance was soon to end. But don’t write off the branded treatment just yet, analysts at Cantor Fitzgerald say, citing "market complexities."

Webinar: Formulation Strategies: Moving IV to SQ & Vial to PFS

Wednesday, February 16 | 9am ET / 6am PT / 3pm CET

Improving patient compliance is a goal for many biopharma companies. In this webinar, experts will discuss the formulation development challenges, considerations, and potential solutions associated with IV to SQ transitions, as well as vial to PFS, to ensure the product’s safety and efficacy. Register Now.